The Endocrine Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Test (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test, Others), By Technology (Tandem Mass Spectrometry, Immunoassay, Monoclonal & Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Others), By End-User (Hospitals, Commercial Laboratories, Ambulatory Care Centers, Others).
The endocrine testing market in 2024 addresses the demand for diagnostic tests and assays used to evaluate the function, hormone levels, and health of the endocrine system, including glands such as the thyroid, pancreas, adrenal glands, and pituitary gland. Endocrine testing plays a crucial role in diagnosing endocrine disorders, hormonal imbalances, and metabolic conditions such as diabetes, thyroid dysfunction, and adrenal insufficiency. Market dynamics are driven by factors such as the increasing prevalence of endocrine disorders, the growing demand for personalized medicine and targeted therapies, and advancements in laboratory automation, immunoassay technology, and molecular diagnostics for improved accuracy and efficiency in hormone testing. Collaboration between endocrine testing manufacturers, clinical laboratories, and endocrinologists drives innovation and market expansion in endocrine testing, supporting early detection, treatment optimization, and disease management in endocrinology and metabolic medicine.
A significant trend in the Endocrine Testing market is the rising demand for point-of-care testing solutions for endocrine disorders. With the increasing prevalence of endocrine disorders such as diabetes, thyroid dysfunction, and adrenal disorders, there is a growing need for rapid and convenient diagnostic tests that can be performed at the point of care, including physician offices, clinics, and retail pharmacies. This trend is driven by factors such as the growing burden of chronic diseases, rising healthcare costs, and the shift towards decentralized healthcare delivery models. Additionally, advancements in technology have led to the development of portable, user-friendly, and cost-effective point-of-care testing devices that offer accurate and reliable results within minutes, enabling timely diagnosis, monitoring, and management of endocrine conditions. As healthcare providers and patients seek more accessible and convenient testing options, the demand for point-of-care endocrine testing solutions is expected to grow, shaping the future of the market.
A key driver in the Endocrine Testing market is the increasing incidence of endocrine disorders and metabolic diseases globally. Endocrine disorders, including diabetes mellitus, thyroid dysfunction, adrenal insufficiency, and hormonal imbalances, affect millions of individuals worldwide and contribute to significant morbidity, mortality, and healthcare costs. This driver is fueled by factors such as aging population, sedentary lifestyles, unhealthy dietary habits, environmental exposures, and genetic predisposition, which contribute to the rising prevalence of metabolic disorders and hormonal imbalances. Additionally, the growing awareness of endocrine health issues and the importance of early detection and treatment are driving increased screening and diagnostic testing for endocrine conditions. As healthcare systems strive to address the growing burden of chronic diseases and metabolic disorders, the demand for endocrine testing solutions is expected to rise, supporting market growth in this segment.
An opportunity for growth in the Endocrine Testing market lies in the adoption of novel biomarkers and advanced assay technologies to improve diagnostic accuracy, expand testing capabilities, and enhance patient care. With ongoing advancements in biomarker discovery, genomics, proteomics, and molecular diagnostics, there is a growing opportunity to identify and validate new biomarkers associated with endocrine function and dysfunction. These biomarkers can provide valuable insights into disease pathogenesis, prognosis, and treatment response, enabling more precise and personalized management of endocrine disorders. Additionally, the development of innovative assay platforms, such as next-generation sequencing, mass spectrometry, and microfluidic technologies, offers new opportunities to improve the sensitivity, specificity, and multiplexing capabilities of endocrine tests. By embracing opportunities to integrate novel biomarkers and advanced assay technologies into endocrine testing solutions, manufacturers can enhance diagnostic performance, expand market reach, and address unmet clinical needs in endocrine care. As research continues to uncover new biomarkers and technological innovations drive assay development, the potential for innovation and market growth in this space is substantial, offering opportunities for improved diagnostic accuracy, patient outcomes, and healthcare delivery efficiency.
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AB Sciex
Abbott Laboratories
Agilent Technologies Inc
bioMerieux SA
Bio-Rad Laboratories Inc
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Laboratory Corp of America Holdings
Ortho Clinical Diagnostics
Quest Diagnostics Inc
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Endocrine Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Endocrine Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Endocrine Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Endocrine Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Endocrine Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Endocrine Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Endocrine Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Endocrine Testing Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Endocrine Testing Market Industry
4.2 Key Market Trends in Endocrine Testing Market Industry
4.3 Potential Opportunities in Endocrine Testing Market Industry
4.4 Key Challenges in Endocrine Testing Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Endocrine Testing Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Endocrine Testing Market Outlook By Segments
7.1 Endocrine Testing Market Outlook by Segments
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
8 North America Endocrine Testing Market Analysis And Outlook To 2030
8.1 Introduction to North America Endocrine Testing Markets in 2024
8.2 North America Endocrine Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Endocrine Testing Market size Outlook by Segments, 2021-2030
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
9 Europe Endocrine Testing Market Analysis And Outlook To 2030
9.1 Introduction to Europe Endocrine Testing Markets in 2024
9.2 Europe Endocrine Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Endocrine Testing Market Size Outlook By Segments, 2021-2030
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
10 Asia Pacific Endocrine Testing Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Endocrine Testing Markets in 2024
10.2 Asia Pacific Endocrine Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Endocrine Testing Market size Outlook by Segments, 2021-2030
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
11 South America Endocrine Testing Market Analysis And Outlook To 2030
11.1 Introduction to South America Endocrine Testing Markets in 2024
11.2 South America Endocrine Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Endocrine Testing Market size Outlook by Segments, 2021-2030
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
12 Middle East And Africa Endocrine Testing Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Endocrine Testing Markets in 2024
12.2 Middle East and Africa Endocrine Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Endocrine Testing Market size Outlook by Segments, 2021-2030
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AB Sciex
Abbott Laboratories
Agilent Technologies Inc
bioMerieux SA
Bio-Rad Laboratories Inc
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Laboratory Corp of America Holdings
Ortho Clinical Diagnostics
Quest Diagnostics Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Test
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Progesterone Test
Testosterone Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Cortisol Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Clinical Chemistry
Others
By End-User
Hospitals
Commercial Laboratories
Ambulatory Care Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Endocrine Testing Market is one of the lucrative growth markets, poised to register a 9.1% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AB Sciex, Abbott Laboratories, Agilent Technologies Inc, bioMerieux SA, Bio-Rad Laboratories Inc, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Laboratory Corp of America Holdings, Ortho Clinical Diagnostics, Quest Diagnostics Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume